Negative pressure wound therapy is a method for promoting wound healing by closing and applying negative pressure to the wound to protect the wound surface, promote granulation tissue formation, and remove the exudate and infectious waste products. Special equipment known as V.A.C.®ATS Therapy System (KCI USA, Inc., San Antonio, USA) has recently been developed for negative pressure wound therapy and has come into wide use.
  The fibroblast growth factor (FGF) trafermin is a therapeutic agent that works well for bedsores and skin ulcers by promoting the growth of fibroblasts and by specifically binding with FGF receptors present in the vascular endothelial cells and fibroblast cells; further, trafermin promotes angiogenesis and granulation tissue formation. We encountered a patient with a bedsore of the National Pressure Ulcer Advisory Panel classification state IV with damages to the joint cavity and the body cavity. Negative pressure wound therapy was selected for promoting granulation tissue formation. We studied the advantages, including whether the use of trafermin has a favorable effect on wound healing, as well as disadvantages of producing possible side effect.